HEARTFLOW, INC.

Lobbying for HEARTFLOW, INC. · Medical device firm in the cardiology space

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 21, 2026

Expenses

$100,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1399
Health Tech Investment Act
HR 6197
Health Tech Investment Act
HR 9260
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027

Lobbying activity 1

Medicare/Medicaid

Issues related to physician payments; issues related to Medicare reimbursement; issues related to Medicare reimbursement of AI-enabled technology; Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343); Health Tech Investment Act (S. 1399/H.R. 6197); H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, issues related to health care, generally.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.